Eusol Biotech
Taipei, Taiwan· Est.
Taiwanese biotech advancing rhFGF1‑based therapies for nerve regeneration and niche generics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese biotech advancing rhFGF1‑based therapies for nerve regeneration and niche generics.
NeurologyPainCardiovascularPsychiatry
Technology Platform
Recombinant human acid fibroblast growth factor (rhFGF1) protein production and formulation for neuro‑regenerative and specialty therapeutic applications.
Opportunities
Successful Phase 3 approval of ES135 could unlock a high‑value niche in neuro‑regeneration, while generic co‑development offers immediate cash flow and market diversification.
Risk Factors
Phase 3 clinical outcomes, reliance on third‑party manufacturers, and limited capital compared with larger multinational peers pose significant execution risks.
Competitive Landscape
Eusol competes with a handful of growth‑factor and nerve‑repair firms; its differentiation lies in a proprietary rhFGF1 platform and early clinical validation in spinal cord injury.